The first generation of AR inhibitors approved by the American Food and Drug Administration (FDA) for prostate cancer treatment included bicalutamide, flutamide, and nilutamide, which were launched between 1989 and 1996 [38]. The gene discussed is AR; the disease is prostate cancer.